{"entity":{"id":"nct04562389","kind":"trial","name":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","aka":[],"tldr":"A phase 3 trial of Selinexor and Ruxolitinib in myeloproliferative neoplasms, run by Karyopharm Therapeutics Inc, active and no longer recruiting.","summary":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis is a phase 3 interventional study registered as NCT04562389 by Karyopharm Therapeutics Inc, with 353 participants enrolled, started 2021-03-11 and due to reach its primary completion in 2026-02-20. Interventions recorded: Selinexor and Ruxolitinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04562389","url":"https://clinicaltrials.gov/study/NCT04562389"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["selinexor","ruxolitinib"],"companies":["karyopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04562389","phase":"3","setting":"A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis","sponsor":"Karyopharm Therapeutics Inc","enrolled":353,"outcomes":[]},"route":"/trials/nct04562389/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/"},{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/"}],"company":[{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/"}]}}